CN112546218A - Liquid dressing formula for auxiliary treatment of vaginitis - Google Patents
Liquid dressing formula for auxiliary treatment of vaginitis Download PDFInfo
- Publication number
- CN112546218A CN112546218A CN202110081509.3A CN202110081509A CN112546218A CN 112546218 A CN112546218 A CN 112546218A CN 202110081509 A CN202110081509 A CN 202110081509A CN 112546218 A CN112546218 A CN 112546218A
- Authority
- CN
- China
- Prior art keywords
- extract
- percent
- vaginitis
- liquid dressing
- igy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010046914 Vaginal infection Diseases 0.000 title claims abstract description 45
- 201000008100 Vaginitis Diseases 0.000 title claims abstract description 45
- 239000007788 liquid Substances 0.000 title claims abstract description 43
- 102000006395 Globulins Human genes 0.000 claims abstract description 28
- 108010044091 Globulins Proteins 0.000 claims abstract description 28
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 28
- 239000000843 powder Substances 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 25
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 25
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 25
- 241000208680 Hamamelis mollis Species 0.000 claims abstract description 25
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 25
- -1 alkyl glycoside Chemical class 0.000 claims abstract description 25
- 229940069521 aloe extract Drugs 0.000 claims abstract description 25
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 25
- 229940119217 chamomile extract Drugs 0.000 claims abstract description 25
- 235000020221 chamomile extract Nutrition 0.000 claims abstract description 25
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims abstract description 25
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims abstract description 25
- 229930182470 glycoside Natural products 0.000 claims abstract description 25
- 229940041616 menthol Drugs 0.000 claims abstract description 25
- 229940118846 witch hazel Drugs 0.000 claims abstract description 25
- 241000246044 Sophora flavescens Species 0.000 claims abstract description 13
- 238000009098 adjuvant therapy Methods 0.000 claims abstract description 11
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 claims abstract description 3
- 241000219784 Sophora Species 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 241000222122 Candida albicans Species 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000207201 Gardnerella vaginalis Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 229940095731 candida albicans Drugs 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 238000002360 preparation method Methods 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000006374 Uterine Cervicitis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a liquid dressing formula for adjuvant therapy of vaginitis, which comprises the following components (in percentage by mass): 0.1 to 0.5 percent of lightyellow sophora root extract, 0.1 to 0.5 percent of chamomile extract, 0.1 to 0.5 percent of witch hazel extract, 0.1 to 0.5 percent of aloe extract, 0.01 to 0.05 percent of menthol, 0.01 to 0.05 percent of alkyl glycoside, 0.01 to 0.05 percent of trehalose, 0.01 to 0.5 percent of yolk globulin powder (IgY), 0.01 to 0.05 percent of edible essence, 0.005 to 0.15 percent of chlorhexidine gluconate and the balance of pure water; the liquid dressing for the auxiliary treatment of the vaginitis is prepared by uniformly dissolving and mixing a sophora flavescens extract, a chamomile extract, a witch hazel extract, an aloe extract, menthol, alkyl glycoside, trehalose, yolk globulin powder (IgY), edible essence and chlorhexidine gluconate into pure water according to a scientific and reasonable ratio.
Description
Technical Field
The invention relates to the technical field of auxiliary treatment of vaginitis, in particular to a liquid dressing formula for auxiliary treatment of vaginitis.
Background
Vaginitis is a common gynecological disease, is easy to repeatedly attack, has various symptoms, and can induce cervicitis and cervical HPV infection and even cause cervical canceration if not effectively treated in time.
Vaginitis is often combined with bacterial and fungal complex infection, so that multiple antibiotics and/or antifungal medicines are usually used for treatment, and the use of multiple antibiotics aggravates fungal infection and destroys normal vaginal flora, thereby affecting curative effect and bringing side effect.
The invention selects a non-antibiotic formula, treats common pathogenic bacteria causing vaginitis specifically, and provides a scientific solution for clinicians.
Disclosure of Invention
The invention aims to provide a liquid dressing formula for assisting in treating vaginitis so as to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a liquid dressing formula for assisting in treating vaginitis comprises the following components (in percentage by mass): 0.1 to 0.5 percent of lightyellow sophora root extract, 0.1 to 0.5 percent of chamomile extract, 0.1 to 0.5 percent of witch hazel extract, 0.1 to 0.5 percent of aloe extract, 0.01 to 0.05 percent of menthol, 0.01 to 0.05 percent of alkyl glycoside, 0.01 to 0.05 percent of trehalose, 0.01 to 0.5 percent of yolk globulin powder (IgY), 0.01 to 0.05 percent of edible essence, 0.005 to 0.15 percent of chlorhexidine gluconate and the balance of pure water.
Wherein, 0.2 percent of sophora flavescens extract, 0.2 percent of chamomile extract, 0.3 percent of witch hazel extract, 0.3 percent of aloe extract, 0.03 percent of menthol, 0.03 percent of alkyl glycoside, 0.03 percent of trehalose, 0.2 percent of yolk globulin powder (IgY), 0.02 percent of edible essence, 0.12 percent of chlorhexidine gluconate and 98.57 percent of pure water.
Wherein, 0.3 percent of sophora flavescens extract, 0.3 percent of chamomile extract, 0.2 percent of witch hazel extract, 0.2 percent of aloe extract, 0.04 percent of menthol, 0.04 percent of alkyl glycoside, 0.04 percent of trehalose, 0.4 percent of yolk globulin powder (IgY), 0.03 percent of edible essence, 0.13 percent of chlorhexidine gluconate and 98.32 percent of pure water.
Wherein, 0.4 percent of sophora flavescens extract, 0.4 percent of chamomile extract, 0.4 percent of witch hazel extract, 0.4 percent of aloe extract, 0.03 percent of menthol, 0.03 percent of alkyl glycoside, 0.03 percent of trehalose, 0.4 percent of yolk globulin powder (IgY), 0.03 percent of edible essence, 0.14 percent of chlorhexidine gluconate and 97.74 percent of pure water.
Wherein the yolk globulin powder (IgY) is used for inhibiting haemophilus vaginalis, staphylococcus aureus, escherichia coli and candida albicans.
A preparation method of a liquid dressing formula for assisting in treating vaginitis comprises the following steps:
s1, weighing radix sophorae flavescentis extract, chamomile extract, witch hazel extract, aloe extract, menthol, alkyl glycoside, trehalose, yolk globulin powder (IgY), edible essence and chlorhexidine gluconate respectively according to the weight by an electronic scale, then adding the weighed radix sophorae flavescentis extract, chamomile extract, witch hazel extract, aloe extract, menthol, alkyl glycoside, trehalose, yolk globulin powder (IgY), edible essence and chlorhexidine gluconate into a double-crankshaft mixer in sequence, and uniformly mixing the radix sophorae flavescentis extract, the chamomile extract, the witch hazel extract, the aloe extract, the menthol, the alkyl glycoside, the trehalose, the yolk globulin powder (IgY), the edible essence and the chlorhexidine gluconate by a double-crankshaft mixer to form an initial raw material;
s2, weighing pure water according to the weight, adding the weighed pure water into a reaction kettle, adjusting the temperature of the reaction kettle to 35-45 ℃, adding the initial raw material prepared in the step S1 into the reaction kettle after the temperature of the pure water in the reaction kettle is raised to 40 ℃, and stirring for 30-35 minutes by using the reaction kettle at 35-45 ℃ to dissolve the initial raw material into the pure water, thereby obtaining the liquid dressing for assisting in treating vaginitis.
Compared with the prior art, the invention has the beneficial effects that:
the sophora flavescens extract, the chamomile extract, the witch hazel extract, the aloe extract, the menthol, the alkyl glycoside, the trehalose, the yolk globulin powder (IgY), the edible essence and the chlorhexidine gluconate are uniformly dissolved and mixed in pure water by a scientific and reasonable ratio to prepare the liquid dressing for the auxiliary treatment of the vaginitis.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Embodiment 1, this embodiment provides a technical solution: a liquid dressing formula for assisting in treating vaginitis comprises the following components (in percentage by mass): 0.2% of sophora flavescens extract, 0.2% of chamomile extract, 0.3% of witch hazel extract, 0.3% of aloe extract, 0.03% of menthol, 0.03% of alkyl glycoside, 0.03% of trehalose, 0.2% of yolk globulin powder (IgY), 0.02% of edible essence, 0.12% of chlorhexidine gluconate and 98.57% of pure water.
Wherein the yolk globulin powder (IgY) is used for inhibiting Haemophilus vaginalis, Staphylococcus aureus, Escherichia coli and Candida albicans.
Wherein, common pathogenic bacteria (haemophilus vaginalis, staphylococcus aureus, escherichia coli and candida albicans) which cause vaginitis are specifically neutralized, at least two kinds of broad-spectrum antibiotics are usually needed for the pathogenic bacteria, and the normal beneficial flora of the vagina can be destroyed.
A preparation method of a liquid dressing formula for assisting in treating vaginitis comprises the following steps:
s1, weighing radix sophorae flavescentis extract, chamomile extract, witch hazel extract, aloe extract, menthol, alkyl glycoside, trehalose, yolk globulin powder (IgY), edible essence and chlorhexidine gluconate respectively according to the weight by an electronic scale, then adding the weighed radix sophorae flavescentis extract, chamomile extract, witch hazel extract, aloe extract, menthol, alkyl glycoside, trehalose, yolk globulin powder (IgY), edible essence and chlorhexidine gluconate into a double-crankshaft mixer in sequence, and uniformly mixing the radix sophorae flavescentis extract, the chamomile extract, the witch hazel extract, the aloe extract, the menthol, the alkyl glycoside, the trehalose, the yolk globulin powder (IgY), the edible essence and the chlorhexidine gluconate by a double-crankshaft mixer to form an initial raw material;
s2, weighing pure water according to the weight, adding the weighed pure water into a reaction kettle, adjusting the temperature of the reaction kettle to 35-45 ℃, adding the initial raw materials prepared in the step S1 into the reaction kettle after the temperature of the pure water in the reaction kettle is raised to 40 ℃, and stirring for 30-35 minutes by using the reaction kettle at 35-45 ℃ to dissolve the initial raw materials into the pure water, thereby obtaining the liquid dressing for auxiliary treatment of vaginitis.
Embodiment 2, this embodiment provides a technical solution: a liquid dressing formula for assisting in treating vaginitis comprises the following components (in percentage by mass): 0.3% of sophora flavescens extract, 0.3% of chamomile extract, 0.2% of witch hazel extract, 0.2% of aloe extract, 0.04% of menthol, 0.04% of alkyl glycoside, 0.04% of trehalose, 0.4% of yolk globulin powder (IgY), 0.03% of edible essence, 0.13% of chlorhexidine gluconate and 98.32% of pure water.
The preparation method of the liquid dressing for the adjuvant therapy of vaginitis is basically the same as that of the liquid dressing for the adjuvant therapy of vaginitis in the embodiment 1, and the difference is only that the component proportion is different.
Embodiment 3, this embodiment provides a technical solution: a liquid dressing formula for assisting in treating vaginitis comprises the following components (in percentage by mass): 0.4% of sophora flavescens extract, 0.4% of chamomile extract, 0.4% of witch hazel extract, 0.4% of aloe extract, 0.03% of menthol, 0.03% of alkyl glycoside, 0.03% of trehalose, 0.4% of yolk globulin powder (IgY), 0.03% of edible essence, 0.14% of chlorhexidine gluconate and 97.74% of pure water.
The preparation method of the liquid dressing for the adjuvant therapy of vaginitis is basically the same as that of the liquid dressing for the adjuvant therapy of vaginitis in the embodiment 1, and the difference is only that the component proportion is different.
Comparative example 1, this example provides a solution: a liquid dressing formula for assisting in treating vaginitis comprises the following components (in percentage by mass): 0.4% of sophora flavescens extract, 0.4% of chamomile extract, 0.4% of witch hazel extract, 0.4% of aloe extract, 0.03% of menthol, 0.03% of alkyl glycoside, 0.03% of trehalose, 0.03% of edible essence and 98.28% of pure water.
The preparation method of the liquid dressing for the adjuvant therapy of vaginitis is basically the same as that of the liquid dressing for the adjuvant therapy of vaginitis in the embodiment 1, and the difference is only that the component proportion is different.
Experimental examples, the following are specific tests for therapeutic effects.
The test method comprises the following steps:
collecting 40 women clinically diagnosed with vaginitis, dividing 40 patients into four groups, namely a group A, a group B, a group C and a group D, wherein each group comprises 10 people, and the age of the patient is 35-55 years, taking the liquid dressings for auxiliary treatment of vaginitis obtained in example 1, example 2, example 3 and comparative example 1, the group A corresponds to the liquid dressing for auxiliary treatment of vaginitis obtained in example 1, the group B corresponds to the liquid dressing for auxiliary treatment of vaginitis obtained in example 2, the group C corresponds to the liquid dressing for auxiliary treatment of vaginitis obtained in example 3, and the group D corresponds to the liquid dressing for auxiliary treatment of vaginitis obtained in proportion 1, and the liquid dressings for auxiliary treatment of vaginitis obtained in doctor are used according to the requirements of doctors (the using time is 1 treatment course).
And (3) checking and analyzing: the results of the revisit are shown in the following table after the product of the invention is used for 1 course of treatment according to the requirements of doctors.
As can be seen from the above table, the liquid dressing for adjuvant therapy of vaginitis prepared by the present invention has a good therapeutic effect on cervicitis, and by comparing examples 1-3 with comparative example 1, the function of the liquid for preventing gynecological inflammation is improved by adding egg yolk globulin powder (IgY) and chlorhexidine gluconate to the liquid dressing for adjuvant therapy of vaginitis prepared by the present invention, so that the therapeutic effect of the liquid dressing for adjuvant therapy of vaginitis is significantly improved.
In conclusion, the sophora flavescens extract, the chamomile extract, the witch hazel extract, the aloe extract, the menthol, the alkyl glycoside, the trehalose, the yolk globulin powder (IgY), the edible essence and the chlorhexidine gluconate are uniformly dissolved and mixed in pure water by a scientific and reasonable ratio to prepare the liquid dressing for the auxiliary treatment of the vaginitis.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (6)
1. The liquid dressing formula for assisting in treating vaginitis is characterized by comprising the following components in percentage by mass: 0.1 to 0.5 percent of lightyellow sophora root extract, 0.1 to 0.5 percent of chamomile extract, 0.1 to 0.5 percent of witch hazel extract, 0.1 to 0.5 percent of aloe extract, 0.01 to 0.05 percent of menthol, 0.01 to 0.05 percent of alkyl glycoside, 0.01 to 0.05 percent of trehalose, 0.01 to 0.5 percent of yolk globulin powder (IgY), 0.01 to 0.05 percent of edible essence, 0.005 to 0.15 percent of chlorhexidine gluconate and the balance of pure water.
2. The liquid dressing formulation for assisting in the treatment of vaginitis according to claim 1, wherein the liquid dressing formulation consists of the following components: 0.2% of sophora flavescens extract, 0.2% of chamomile extract, 0.3% of witch hazel extract, 0.3% of aloe extract, 0.03% of menthol, 0.03% of alkyl glycoside, 0.03% of trehalose, 0.2% of yolk globulin powder (IgY), 0.02% of edible essence, 0.12% of chlorhexidine gluconate and 98.57% of pure water.
3. The liquid dressing formulation for assisting in the treatment of vaginitis according to claim 1, wherein the liquid dressing formulation consists of the following components: 0.3% of sophora flavescens extract, 0.3% of chamomile extract, 0.2% of witch hazel extract, 0.2% of aloe extract, 0.04% of menthol, 0.04% of alkyl glycoside, 0.04% of trehalose, 0.4% of yolk globulin powder (IgY), 0.03% of edible essence, 0.13% of chlorhexidine gluconate and 98.32% of pure water.
4. The liquid dressing formulation for assisting in the treatment of vaginitis according to claim 1, wherein the liquid dressing formulation consists of the following components: 0.4% of sophora flavescens extract, 0.4% of chamomile extract, 0.4% of witch hazel extract, 0.4% of aloe extract, 0.03% of menthol, 0.03% of alkyl glycoside, 0.03% of trehalose, 0.4% of yolk globulin powder (IgY), 0.03% of edible essence, 0.14% of chlorhexidine gluconate and 97.74% of pure water.
5. The liquid dressing formulation for assisting in the treatment of vaginitis according to claim 1, wherein: the yolk globulin powder (IgY) is used for inhibiting haemophilus vaginalis, staphylococcus aureus, escherichia coli and candida albicans.
6. The method for preparing a liquid dressing formulation for the adjuvant treatment of vaginitis claimed in any one of claims 1 to 5, comprising the following steps:
s1, weighing radix sophorae flavescentis extract, chamomile extract, witch hazel extract, aloe extract, menthol, alkyl glycoside, trehalose, yolk globulin powder (IgY), edible essence and chlorhexidine gluconate respectively according to the weight by an electronic scale, then adding the weighed radix sophorae flavescentis extract, chamomile extract, witch hazel extract, aloe extract, menthol, alkyl glycoside, trehalose, yolk globulin powder (IgY), edible essence and chlorhexidine gluconate into a double-crankshaft mixer in sequence, and uniformly mixing the radix sophorae flavescentis extract, the chamomile extract, the witch hazel extract, the aloe extract, the menthol, the alkyl glycoside, the trehalose, the yolk globulin powder (IgY), the edible essence and the chlorhexidine gluconate by a double-crankshaft mixer to form an initial raw material;
s2, weighing pure water according to the weight, adding the weighed pure water into a reaction kettle, adjusting the temperature of the reaction kettle to 35-45 ℃, adding the initial raw material prepared in the step S1 into the reaction kettle after the temperature of the pure water in the reaction kettle is raised to 40 ℃, and stirring for 30-35 minutes by using the reaction kettle at 35-45 ℃ to dissolve the initial raw material into the pure water, thereby obtaining the liquid dressing for assisting in treating vaginitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110081509.3A CN112546218A (en) | 2021-01-21 | 2021-01-21 | Liquid dressing formula for auxiliary treatment of vaginitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110081509.3A CN112546218A (en) | 2021-01-21 | 2021-01-21 | Liquid dressing formula for auxiliary treatment of vaginitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112546218A true CN112546218A (en) | 2021-03-26 |
Family
ID=75035720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110081509.3A Pending CN112546218A (en) | 2021-01-21 | 2021-01-21 | Liquid dressing formula for auxiliary treatment of vaginitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112546218A (en) |
-
2021
- 2021-01-21 CN CN202110081509.3A patent/CN112546218A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102068640B (en) | Externally-applied traditional Chinese medicine and preparation method thereof | |
| CN109432481A (en) | A kind of polyurethane dressing of hemostatic and antibacterial and preparation method thereof | |
| CN112999345A (en) | Formula of gel for preventing and treating cervical HPV infection | |
| CN104147108A (en) | Brown alginate oligosaccharide-containing antibacterial gel | |
| CN112546218A (en) | Liquid dressing formula for auxiliary treatment of vaginitis | |
| CN102652763A (en) | Traditional Chinese medicine preparation for treating burn and scald and preparation method thereof | |
| CN1824081A (en) | External use preparation for treating vulnus slow agglutination and its preparation method | |
| CN104274667A (en) | Traditional Chinese medicine for treating fractures and traumatic wounds | |
| CN111713625A (en) | Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof | |
| CN106177725A (en) | A kind of treat the plaster compositions of mastopathy, purposes and preparation method thereof | |
| CN1935267A (en) | Wound surface active repair material | |
| CN113509493B (en) | Antibacterial ointment for promoting wound healing and preparation method thereof | |
| CN111329892B (en) | Traditional Chinese medicine composition for treating recurrent abortion combined with phospholipid syndrome and application thereof | |
| CN114652748A (en) | Preparation method and application of medical gynecological lotion containing stem cell bacteriostatic factors | |
| CN110215497B (en) | Skin repairing cream and preparation process thereof | |
| CN110227094A (en) | Application of the Flos Albiziae water extract in preparation prevention and treatment gynaecological imflammation disease external drug | |
| CN1935157B (en) | Medical stone emulsifiable paste for treating skin disease and its preparing method | |
| CN105168503B (en) | It is a kind of to be used to prevent external medicine composition of radiodermatitis and preparation method thereof | |
| CN107929549A (en) | A kind of hemostat and preparation method thereof | |
| CN105664013A (en) | Raw rhubarb compound external-use pain-relieving and swelling-reducing ointment for traumatic injuries | |
| CN1241629C (en) | External use medicine for treating AIDS virus | |
| CN1939469A (en) | Chinese medicinal plaster with analgetic, hemostatic, repercussive and sarcogenic functions | |
| CN101366922B (en) | Proprietary Chinese medicine for treating empyrosis | |
| CN114053363A (en) | Traditional Chinese medicine composition for treating red swelling and hot pain and application thereof | |
| CN113940948A (en) | Ointment for treating burn and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB03 | Change of inventor or designer information |
Inventor after: Fan Guichao Inventor before: Fan Guichao |
|
| CB03 | Change of inventor or designer information | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210326 |
|
| WD01 | Invention patent application deemed withdrawn after publication |